124 related articles for article (PubMed ID: 29575357)
41. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.
Trunzer K; Pavlick AC; Schuchter L; Gonzalez R; McArthur GA; Hutson TE; Moschos SJ; Flaherty KT; Kim KB; Weber JS; Hersey P; Long GV; Lawrence D; Ott PA; Amaravadi RK; Lewis KD; Puzanov I; Lo RS; Koehler A; Kockx M; Spleiss O; Schell-Steven A; Gilbert HN; Cockey L; Bollag G; Lee RJ; Joe AK; Sosman JA; Ribas A
J Clin Oncol; 2013 May; 31(14):1767-74. PubMed ID: 23569304
[TBL] [Abstract][Full Text] [Related]
42. Toxic epidermal necrolysis induced by vemurafenib after nivolumab failure.
Arenbergerova M; Mrazova I; Horazdovsky J; Sticova E; Fialova A; Arenberger P
J Eur Acad Dermatol Venereol; 2017 May; 31(5):e253-e254. PubMed ID: 27739125
[No Abstract] [Full Text] [Related]
43. Patient-derived tumor xenograft model to guide the use of BRAF inhibitors in metastatic melanoma.
Guerreschi P; Scalbert C; Qassemyar A; Kluza J; Ravasi L; Huglo D; Martinot-Duquennoy V; Formstecher P; Marchetti P; Mortier L
Melanoma Res; 2013 Oct; 23(5):373-80. PubMed ID: 23852164
[TBL] [Abstract][Full Text] [Related]
44. Cytochrome P450 1A1 and 1B1 in human blood lymphocytes are not suitable as biomarkers of exposure to dioxin-like compounds: polymorphisms and interindividual variation in expression and inducibility.
van Duursen MB; Sanderson JT; van den Berg M
Toxicol Sci; 2005 May; 85(1):703-12. PubMed ID: 15659568
[TBL] [Abstract][Full Text] [Related]
45. Chloracne and Hyperpigmentation Caused by Exposure to Hazardous Aryl Hydrocarbon Receptor Ligands.
Furue M; Tsuji G
Int J Environ Res Public Health; 2019 Dec; 16(23):. PubMed ID: 31816860
[TBL] [Abstract][Full Text] [Related]
46. Inflammatory and chloracne-like skin lesions in B6C3F1 mice exposed to 3,3',4,4'-tetrachloroazobenzene for 2 years.
Ramot Y; Nyska A; Lieuallen W; Maly A; Flake G; Kissling GE; Brix A; Malarkey DE; Hooth MJ
Toxicology; 2009 Nov; 265(1-2):1-9. PubMed ID: 19737593
[TBL] [Abstract][Full Text] [Related]
47. From the Cover: High Susceptibility of Lrig1 Sebaceous Stem Cells to TCDD in Mice.
Fontao F; Barnes L; Kaya G; Saurat JH; Sorg O
Toxicol Sci; 2017 Dec; 160(2):230-243. PubMed ID: 28973660
[TBL] [Abstract][Full Text] [Related]
48. Keratoacanthoma, palmoplantar keratoderma developing in an advanced melanoma patient treated with vemurafenib regressed by blockade of mitogen-activated protein kinase kinase signaling.
Furudate S; Fujimura T; Kambayashi Y; Hidaka T; Sato Y; Tanita K; Hashimoto A; Aiba S
J Dermatol; 2017 Sep; 44(9):e226-e227. PubMed ID: 28439948
[No Abstract] [Full Text] [Related]
49. N-Ras mutation in vemurafenib-associated expanding melanocytic nevus.
Harada K; Kato Y; Maeda T; Yoshida M; Irisawa R; Nagao T; Tsuboi R
J Dermatol; 2017 May; 44(5):e101-e102. PubMed ID: 27790745
[No Abstract] [Full Text] [Related]
50. Cutaneous adverse event associated with vemurafenib in a 3-year-old pediatric patient with BRAF mutation-positive metastatic melanoma and factor X deficiency.
Büyükkapu Bay S; Kebudi R; Zülfikar B
Melanoma Res; 2019 Feb; 29(1):99-101. PubMed ID: 30376464
[TBL] [Abstract][Full Text] [Related]
51. Nonmalignant cutaneous findings associated with vemurafenib use in patients with metastatic melanoma.
Boyd KP; Vincent B; Andea A; Conry RM; Hughey LC
J Am Acad Dermatol; 2012 Dec; 67(6):1375-9. PubMed ID: 22940405
[TBL] [Abstract][Full Text] [Related]
52. A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain Metastases.
Harding JJ; Catalanotti F; Munhoz RR; Cheng DT; Yaqubie A; Kelly N; McDermott GC; Kersellius R; Merghoub T; Lacouture ME; Carvajal RD; Panageas KS; Berger MF; Rosen N; Solit DB; Chapman PB
Oncologist; 2015 Jul; 20(7):789-97. PubMed ID: 25956405
[TBL] [Abstract][Full Text] [Related]
53. Hair and nail adverse events during treatment with targeted therapies for metastatic melanoma.
Dika E; Patrizi A; Ribero S; Fanti PA; Starace M; Melotti B; Sperandi F; Piraccini BM
Eur J Dermatol; 2016 Jun; 26(3):232-9. PubMed ID: 27019511
[TBL] [Abstract][Full Text] [Related]
54. Effects of dioxin isomers on induction of AhRs and CYP1A1 in early developmental stage embryos of medaka (Oryzias latipes).
Hanno K; Oda S; Mitani H
Chemosphere; 2010 Feb; 78(7):830-9. PubMed ID: 20060563
[TBL] [Abstract][Full Text] [Related]
55. Dramatic response of vemurafenib-induced cutaneous lesions upon switch to dual BRAF/MEK inhibition in a metastatic melanoma patient.
Peters S; Bouchaab H; Zimmerman S; Bucher M; Gaide O; Letovanec I; Homicsko K; Michielin O
Melanoma Res; 2014 Oct; 24(5):496-500. PubMed ID: 25185693
[TBL] [Abstract][Full Text] [Related]
56. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.
Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion-Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
Lancet Oncol; 2018 May; 19(5):603-615. PubMed ID: 29573941
[TBL] [Abstract][Full Text] [Related]
57. Vemurafenib sensitivity skin reaction after ipilimumab.
Harding JJ; Pulitzer M; Chapman PB
N Engl J Med; 2012 Mar; 366(9):866-8. PubMed ID: 22375995
[No Abstract] [Full Text] [Related]
58. A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib.
Graziani G; Artuso S; De Luca A; Muzi A; Rotili D; Scimeca M; Atzori MG; Ceci C; Mai A; Leonetti C; Levati L; Bonanno E; Tentori L; Caccuri AM
Biochem Pharmacol; 2015 May; 95(1):16-27. PubMed ID: 25795251
[TBL] [Abstract][Full Text] [Related]
59. Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAF
Blank CU; Larkin J; Arance AM; Hauschild A; Queirolo P; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Garbe C; Chiarion Sileni V; Mandalà M; Gogas H; Espinosa E; Hospers GAP; Miller WH; Robson S; Makrutzki M; Antic V; Brown MP
Eur J Cancer; 2017 Jul; 79():176-184. PubMed ID: 28501764
[TBL] [Abstract][Full Text] [Related]
60. An acneiform eruption exhibiting locus minoris resistentiae after whole-brain radiation and vemurafenib therapy.
Noell C; Chen C; Sells R; Mikailov A; Kroshinsky D
J Eur Acad Dermatol Venereol; 2017 Apr; 31(4):e209-e210. PubMed ID: 27717016
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]